Skip to main content

Table 1 Mutations in ASXL1 gene in published studies

From: Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases

Selected Ref.

MDS

n (%)

CMML

n (%)

MPN

n (%)

Secondary AML

n (%)

De novo AML

n (%)

*Abdel-Wahab et al., [25]

   

12/63 (19.3)

 

*Abdel-Wahab et al., [18]

 

3/24 (12.5)

3/46 PMF (6.5)

  

BĂ©jar et al., [21]

63/439 (14.4)

    

Brecqueville et al., [26]

  

17/149 (11.4): 6/30 PMF (20), 2/30 PV (7), 2/53 ET (4),

  

Boultwood et al., [5]

28/182 (15.4)

17/51 (33.3)

 

9/40 (22.5)

8/27 (29.6)

Boultwood et al., [27]

  

+6/41 (CML) (14.6)

  

Carbuccia et al., [28]

  

5/64 (7.8)

  

Carbuccia et al., [20]

   

9/17 (58)

3/46 (6)

Chou et al., [29]

    

54/501 (10.8)

Gelsi-Boyer et al., [1]

4/35 (11.4)

17/39 (43.6)

   

Gelsi-Boyer et al., [30]

 

25/53 (47.2)

   

Grossmann et al., [31]

 

41/79 (52)

   

Jankowsa et al.,[32]

 

24/52 (46)

   

Pratcorona et al., [33]

   

3/24 (12.5)

35/775 (4.5)

Ricci et al.,[34]

  

23/42 PMF (54.8)

  

Rocquain et al., [22]

13/65 (20)

  

9/18 (50)

3/46 (6.5)

Shen et al., [35]

    

27/605 (4.5)

Stein et al., [36]

  

12/47 PMF (25.5)

1/42 PV (2)

  

Thol et al., [37]

40/193 (20.7)

    

Total*

148/914 (16.2)

124/274 (45)

41/119 PMF (34.5)

30/99 (30.3)

130/2000 (6.5)

  1. * not included in final count because p.Gly646TrpfsX12 had not been taken into account; + including CML cases